Which lab markers are typically assessed in the endocrine evaluation after menopause?

The assessment of lab markers in the endocrine evaluation after menopause is primarily focused on hormones that reflect changes in the ovarian function and overall hormonal balance following the cessation of menstruation. The most relevant markers utilized in this context are Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

After menopause, the ovaries reduce their production of estrogen and progesterone significantly. This leads to an increase in the levels of FSH and LH, which are hormones produced by the pituitary gland that drive ovarian activity. In the absence of sufficient ovarian hormone production, the feedback mechanism causes the pituitary to produce more FSH and LH, making these hormones key indicators of menopause and its progression.

Estradiol and progesterone are generally lower post-menopause, and assessing their levels may not provide as much insight into the hormonal changes taking place as FSH and LH. Similarly, markers like AMH and inhibin B are more relevant in the evaluation of ovarian reserve and function, rather than directly indicating menopausal status. Testosterone and cortisol, although important in evaluating overall endocrine health, do not specifically address the menopausal transition and its hormonal implications.

Therefore, FSH and LH are the most pertinent lab markers evaluated in the context